Organon & Co
Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates approximately six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
52 Week high
52 Week low
Business Wire • 4 days ago • OGNOrganon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
Seeking Alpha • 21 days ago • OGN6% Yield And Significantly Undervalued: A Closer Look At Organon
The Motley Fool • 22 days ago • OGN3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Business Wire • 26 days ago • OGNOrganon Bolsters Research & Development Expertise with Two Leadership Appointments
Seeking Alpha • about 2 months ago • OGNOrganon & Co (OGN) Q2 2023 Earnings Call Transcript
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.